Rapt Therapeutics Stock Working Capital

RAPT Stock

USD 1.05 0.02 1.87%

RAPT Therapeutics fundamentals help investors to digest information that contributes to RAPT Therapeutics' financial success or failures. It also enables traders to predict the movement of RAPT Stock. The fundamental analysis module provides a way to measure RAPT Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to RAPT Therapeutics stock.

	Last Reported	Projected for Next Year
Net Working Capital	139.9 M	132.4 M
Change In Working Capital	5.5 M	5.8 M

Change In Working Capital is likely to gain to about 5.8 M in 2024, whereas Net Working Capital is likely to drop slightly above 132.4 M in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

RAPT Therapeutics Company Working Capital Analysis

RAPT Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current RAPT Therapeutics Working Capital

139.95 M

Most of RAPT Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, RAPT Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

RAPT Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for RAPT Therapeutics is extremely important. It helps to project a fair market value of RAPT Stock properly, considering its historical fundamentals such as Working Capital. Since RAPT Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of RAPT Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of RAPT Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Capital Stock	Current Deferred Revenue	Short Term Debt	Short Term Investments	Deferred Long Term Liab
Total Assets		0.95	0.89	0.57	-0.85	0.77	0.89	-0.72	0.95	1.0	1.0	0.91	0.26	0.87	-0.89	0.74	0.92	-0.76
Total Stockholder Equity	0.95		0.87	0.41	-0.84	0.76	0.87	-0.9	1.0	0.95	0.94	0.96	0.53	0.8	-0.81	0.75	0.81	-0.71
Net Tangible Assets	0.89	0.87		0.46	-0.97	0.83	1.0	-0.72	0.87	0.89	0.87	0.9	0.2	0.88	-0.91	0.79	0.77	-0.91
Net Debt	0.57	0.41	0.46		-0.42	0.42	0.45	-0.12	0.41	0.58	0.59	0.36	-0.33	0.49	-0.51	0.67	0.54	-0.4
Retained Earnings	-0.85	-0.84	-0.97	-0.42		-0.9	-0.99	0.7	-0.84	-0.84	-0.82	-0.91	-0.2	-0.91	0.92	-0.74	-0.73	0.95
Accounts Payable	0.77	0.76	0.83	0.42	-0.9		0.85	-0.61	0.76	0.76	0.73	0.87	0.17	0.88	-0.79	0.57	0.54	-0.8
Capital Surpluse	0.89	0.87	1.0	0.45	-0.99	0.85		-0.72	0.87	0.88	0.86	0.91	0.21	0.89	-0.93	0.78	0.78	-0.93
Total Liab	-0.72	-0.9	-0.72	-0.12	0.7	-0.61	-0.72		-0.9	-0.72	-0.7	-0.87	-0.82	-0.56	0.58	-0.64	-0.53	0.54
Net Invested Capital	0.95	1.0	0.87	0.41	-0.84	0.76	0.87	-0.9		0.95	0.94	0.96	0.53	0.8	-0.81	0.75	0.81	-0.71
Total Current Assets	1.0	0.95	0.89	0.58	-0.84	0.76	0.88	-0.72	0.95		1.0	0.9	0.26	0.86	-0.89	0.75	0.92	-0.75
Net Working Capital	1.0	0.94	0.87	0.59	-0.82	0.73	0.86	-0.7	0.94	1.0		0.88	0.25	0.85	-0.88	0.75	0.93	-0.73
Common Stock	0.91	0.96	0.9	0.36	-0.91	0.87	0.91	-0.87	0.96	0.9	0.88		0.47	0.9	-0.87	0.77	0.73	-0.81
Property Plant Equipment	0.26	0.53	0.2	-0.33	-0.2	0.17	0.21	-0.82	0.53	0.26	0.25	0.47		0.06	-0.07	0.19	0.1	-0.04
Capital Stock	0.87	0.8	0.88	0.49	-0.91	0.88	0.89	-0.56	0.8	0.86	0.85	0.9	0.06		-0.96	0.74	0.77	-0.9
Current Deferred Revenue	-0.89	-0.81	-0.91	-0.51	0.92	-0.79	-0.93	0.58	-0.81	-0.89	-0.88	-0.87	-0.07	-0.96		-0.79	-0.87	0.95
Short Term Debt	0.74	0.75	0.79	0.67	-0.74	0.57	0.78	-0.64	0.75	0.75	0.75	0.77	0.19	0.74	-0.79		0.65	-0.73
Short Term Investments	0.92	0.81	0.77	0.54	-0.73	0.54	0.78	-0.53	0.81	0.92	0.93	0.73	0.1	0.77	-0.87	0.65		-0.73
Deferred Long Term Liab	-0.76	-0.71	-0.91	-0.4	0.95	-0.8	-0.93	0.54	-0.71	-0.75	-0.73	-0.81	-0.04	-0.9	0.95	-0.73	-0.73

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict RAPT Therapeutics

Working Capital Over Time

RAPT Capital Surpluse

Capital Surpluse

740.29 Million

At this time, RAPT Therapeutics' Capital Surpluse is comparatively stable compared to the past year.

Based on the company's disclosures, RAPT Therapeutics has a Working Capital of 139.95 M. This is 67.12% lower than that of the Biotechnology sector and 74.02% lower than that of the Health Care industry. The working capital for all United States stocks is 90.53% higher than that of the company.

RAPT Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RAPT Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of RAPT Therapeutics could also be used in its relative valuation, which is a method of valuing RAPT Therapeutics by comparing valuation metrics of similar companies.

RAPT Therapeutics is currently under evaluation in working capital category among its peers.

RAPT Fundamentals

	Return On Equity	-0.8
	Return On Asset	-0.47
	Current Valuation	(55.38 M)
	Shares Outstanding	34.96 M
	Shares Owned By Insiders	1.84 %
	Shares Owned By Institutions	86.65 %
	Number Of Shares Shorted	2.67 M
	Price To Book	0.39 X
	Price To Sales	411.22 X
	Gross Profit	1.53 M
	EBITDA	(125.85 M)
	Net Income	(116.8 M)
	Cash And Equivalents	207.34 M
	Cash Per Share	6.99 X
	Total Debt	6.91 M
	Debt To Equity	0.04 %
	Current Ratio	15.97 X
	Book Value Per Share	2.74 X
	Cash Flow From Operations	(97.05 M)
	Short Ratio	9.95 X
	Earnings Per Share	(2.78) X
	Target Price	2.67
	Number Of Employees	70
	Beta	0.32
	Market Capitalization	37.41 M
	Total Asset	173.33 M
	Retained Earnings	(484.68 M)
	Working Capital	139.95 M
	Current Asset	17 K
	Current Liabilities	167 K
	Net Asset	173.33 M

About RAPT Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze RAPT Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RAPT Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RAPT Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for RAPT Stock Analysis

When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC